RPID Overview

Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission-critical automation solutions to facilitate the manufacturing and release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. Its flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.

Wall Street analysts forecast RPID stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RPID is8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Rapid Micro Biosystems, Inc revenue for the last quarter amounts to 8.00M USD, increased 11.06

Rapid Micro Biosystems, Inc. EPS for the last quarter amounts to -0.31 USD, increased 19.23

Rapid Micro Biosystems, Inc (RPID) has 171 emplpoyees as of May 19 2026.

Today RPID has the market capitalization of 90.26M USD.